Molecular neurodegeneration Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• Cell-specific transcriptional signatures of vascular cells in Alzheimer's disease: perspectives, pathways, and therapeutic directions..  20:-. 2025
• Heparin-enriched plasma proteome is significantly altered in Alzheimer's disease..  19:-. 2024
• Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology..  19:-. 2024
• Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease..  18:-. 2023
• Microglial APOE4: more is less and less is more..  18:-. 2023
• Regulation of cortical hyperexcitability in amyotrophic lateral sclerosis: focusing on glial mechanisms..  18:-. 2023
• Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease..  18:-. 2023
• hiPSC-based models to decipher the contribution of human astrocytes to Alzheimer's disease and potential therapeutics..  18:-. 2023
• APOE effects on regional tau in preclinical Alzheimer's disease..  18:-. 2023
• Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels..  17:-. 2022
• Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy..  17:-. 2022
• Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer's and Parkinson's diseases..  17:-. 2022
• Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (Part 1): the 2021 pre-symposium of the 15th international conference on Alzheimer's and Parkinson's diseases..  17:-. 2022
• LRP1 is a neuronal receptor for α-synuclein uptake and spread..  17:-. 2022
• 17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson's disease are associated with LRRC37A/2 expression in astrocytes..  17:-. 2022
• Imaging tau pathology in Alzheimer's disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies..  17:-. 2022
• Solving neurodegeneration: common mechanisms and strategies for new treatments..  17:-. 2022
• Alzheimer's disease - the journey of a healthy brain into organ failure..  17:-. 2022
• Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis..  17:-. 2022
• Murine roseolovirus does not accelerate amyloid-β pathology and human roseoloviruses are not over-represented in Alzheimer disease brains..  17:-. 2022
• The landscape of human tissue and cell type specific expression and co-regulation of senescence genes..  17:-. 2022
• TDP-43 Pathology in Alzheimer's Disease..  16:-. 2021
• The informed road map to prevention of Alzheimer Disease: A call to arms..  16:-. 2021
• Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy..  16:-. 2021
• A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis..  16:-. 2021
• AIF3 splicing switch triggers neurodegeneration..  16:-. 2021
• A novel systems biology approach to evaluate mouse models of late-onset Alzheimer's disease..  15:-. 2020
• Correction to: Deciphering cellular transcriptional alterations in Alzheimer's disease brains..  15:-. 2020
• Peroxiredoxin 6 mediates protective function of astrocytes in Aβ proteostasis..  15:-. 2020
• Deciphering cellular transcriptional alterations in Alzheimer's disease brains..  15:-. 2020
• Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS..  15:-. 2020
• Organotypic brain slice cultures to model neurodegenerative proteinopathies..  14:-. 2019
• Targeting tauopathy with engineered tau-degrading intrabodies..  14:-. 2019
• Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model..  14:-. 2019
• Dural lymphatics regulate clearance of extracellular tau from the CNS..  14:-. 2019
• ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans..  13:-. 2018
• Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases..  13:-. 2018
• TMEM106B haplotypes have distinct gene expression patterns in aged brain..  13:-. 2018
• Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology..  13:-. 2018
• AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model..  13:-. 2018
• α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism..  13:-. 2018
• Glial contributions to neurodegeneration in tauopathies..  12:-. 2017
• Targeting psychologic stress signaling pathways in Alzheimer's disease..  12:-. 2017
• Diurnal oscillation of CSF Aβ and other AD biomarkers..  12:-. 2017
• The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity..  12:-. 2017
• APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice..  12:-. 2017
• Erratum to: Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation..  12:-. 2017
• Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice..  12:-. 2017
• Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation..  11:-. 2016
• Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains..  11:-. 2016
• Erratum to: A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease..  11:-. 2016
• A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease..  -. 2016
• Analysis of in vivo turnover of tau in a mouse model of tauopathy..  -. 2015
• Effects of CD2-associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model..  -. 2015
• Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow..  -. 2014
• ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease..  -. 2014
• Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2..  -. 2014
• Conformational templating of α-synuclein aggregates in neuronal-glial cultures..  -. 2013
• Normal cognition in transgenic BRI2-Aβ mice..  -. 2013
• In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis..  -. 2013
• Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis..  -. 2012
• Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology..  -. 2012
• Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition..  -. 2012
• Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice..  7:-. 2012
• Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling..  -. 2012
• Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects..  -. 2012
• Amyloid beta protein-induced zinc sequestration leads to synaptic loss via dysregulation of the ProSAP2/Shank3 scaffold..  -. 2011
• Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo..  -. 2011
• Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells..  -. 2010
• Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons..  -. 2009
• Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575..  -. 2009
• "What kills neurons in neurodegenerative diseases?", a review series in an open access journal..  -. 2009
• The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease..  -. 2009
• Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo..  -. 2009
• Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels..  -. 2007
• Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms..  -. 2007
• Signal peptide peptidase (SPP) dimer formation as assessed by fluorescence lifetime imaging microscopy (FLIM) in intact cells..  -. 2006
• Sortilin, SorCS1b, and SorLA Vps10p sorting receptors, are novel gamma-secretase substrates..  -. 2006
• 18F-MK-6240 tau PET in patients at-risk for chronic traumatic encephalopathy 2025

Identity

International Standard Serial Number (ISSN)

• 1750-1326